Gee Lawson News

Researchers have taken a closer look at Longvida® and discovered...

Researchers at Central Michigan University have taken a closer look at Longvida® Optimized Curcumin. Previously, these researchers conducted amyloid binding work in vitro with promising results1. Recently published, in the International Journal of Alzheimer’s Disease, Maiti P et al have compared standard, unformulated curcumin more closely to Longvida®.  The present study, “was designed to compare the neuroprotective effects of unformulated curcumin (95% curcumin equivalent to 80% free curcumin) and/or SLCP™ curcumin (Longvida® with 20% free curcumin), in vitro after exposure to Aβ42.”


Maiti and team brought a fresh perspective to the question: how does Longvida’s free curcumin compare to unformulated free curcumin? With that in mind, the results are even more exciting to see: Longvida’s free curcumin outperformed the unformulated 80% free curcumin in all tested parameters. Longvida® showed greater permeability than 80% in vitro, decreased reactive oxygen species (ROS) production, and prevented apoptic death.2


Next, researchers examined cell death and cell survival markers after exposure to Aβ42. They indicated that, “with Aβ42-treatment, whereas Longvida®, but not 95% curcumin extract, was able to decrease these protein levels.”2 Longvida® was also shown to mediate p-tau after exposure to Aβ42; as they showed that without Longvida®, Aβ42 exposure significantly increased (p>0.01) p-tau.2


“These new studies from Dr.’s Maiti and Dunbar show that the Longvida® formulation retains excellent neuroprotective and amyloid binding activities in vitro. The superior bioavailability and sensitivity of Longvida® in detecting amyloid deposits in brain are consistent with the promising in vivo human clinical trial retinal amyloid imaging results reported by Neurovision and AIBL trial investigators at international meetings,” Dr. Gregory Cole, Interim Director, Mary S Easton Alzheimer Center, Assoc Dir Research GRECC CLA VA, Prof, Depts Neurol and Med, UCLA”


Expanding upon some of these results more in-depth, the researchers stated, “We also monitored the permeability of SLCP™ (Longvida®) and observed that maximum permeability was reached within the first hour of SLCP administration and intensity becomes stable up to 24h after administration,2” which further backs the results of the Swinburne study published in 20153


For Verdure Sciences, producers of Longvida®, it is not only exciting to see these results from Maiti P et al, but absolutely fantastic to have additional support for previous research efforts on Longvida®.  Combined together, these studies show that Longvida’s efficacious free curcumin is delivered in a single daily dose to offer tangible health benefits. The key to the success of Longvida lies within the patented and proprietary Solid Lipid Curcumin Particle Technology, or SLCP.  To learn more about the product, please visit our dedicated page or contact us.



1 Maiti P et al. A comparative study of dietary curcumin, [Longvida®], and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5x-familial mice. Histochem Cell Biol. 2016 Nov. Vol 146(Issue 5): 609-625. EPub 2016 Jul 12. DOI: 10.1007/s00418-016-1464-1

2 Maiti P et al. Comparative neuroprotective effects of dietary curcumin and Solid Lipid Curcumin Particles [Longvida®] in cultured mouse neuroblastoma cells after exposure to Aβ42. Intl J Alz Dis. 2017 Apr 16. Vol 2017(Article ID 4164872): 13 pgs. DOI: 10.1155/2017/4164872

3 Cox KH et al. Investigation of the effects of Solid Lipid Curcumin [Longvida®] on cognition and mood in a healthy older population. Centre for Human Psycopharmacology, Swinburne University. J Psychopharmacol. 2015 May. Vol 29(No 5): 642-651. DOI: 10.1177/0269881114552744